EVolution Therapeutics selected for 2026 Accelerate@Babraham cohort.
EVolution Therapeutics is delighted to announce that we have been selected to join the 2026 Accelerate@Babraham cohort, one of the UK’s leading accelerator programmes for early-stage life science companies.
Accelerating early-stage life science innovation
Accelerate@Babraham supports ambitious life science start-ups as they refine their science, strengthen their commercial strategy and prepare for investment and growth.
Based at Babraham Research Campus in Cambridge, the programme provides access to expert mentoring, investor networks, laboratory space, business support and a wider bioscience ecosystem of companies, researchers and industry partners.
Advancing mRNA therapeutics for inflammatory disease
EVolution Therapeutics joins the cohort at an important stage in our development. We are currently raising pre-seed funding to advance our mRNA therapeutic platform towards IND-enabling studies.
Our platform is built around resolution biology: harnessing the body’s natural pathways to actively resolve dysregulated inflammation and support tissue repair.
Our initial focus is wound healing, where persistent inflammation can prevent normal repair and contribute to long-term disease burden. However, we believe our local mRNA-LNP hydrogel platform has potential across a broader range of inflammatory diseases where immune dysregulation plays a central role.
Building within a world-leading bioscience ecosystem
Dr James Gavin, CEO and Co-founder of EVolution Therapeutics, said:
“Being selected for Accelerate@Babraham is a major milestone for EVolution Therapeutics. The programme provides access to one of the strongest life science ecosystems in the UK, combining expert mentoring, investor insight, laboratory infrastructure and a peer network of ambitious biotech founders.
For a therapeutics company developing a next-generation approach to inflammatory disease, Babraham Research Campus is an outstanding environment in which to build, challenge and accelerate our plans. We are excited to be joining the community and making the most of the opportunity.”
Looking ahead
EVolution Therapeutics is proud to join the 2026 cohort alongside BASE Rx, Elarna Bio, Ribogenyx, Semper-B Therapeutics and Switch Biologics.
We would like to thank the Accelerate@Babraham team for this opportunity and look forward to working with the programme’s mentors, partners and wider network as we continue developing next-generation mRNA therapeutics for inflammatory disease.
Investors and strategic partners interested in mRNA therapeutics, inflammation resolution, wound healing and regenerative medicine are encouraged to get in touch with the EVolution Therapeutics team.